featured
Ibrutinib Plus Rituximab vs Placebo Plus Rituximab for Waldenström's Macroglobulinemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
J. Clin. Oncol 2021 Oct 04;[EPub Ahead of Print], C Buske, A Tedeschi, J Trotman, R García-Sanz, D MacDonald, V Leblond, B Mahe, C Herbaux, JV Matous, CS Tam, LT Heffner, M Varettoni, ML Palomba, C Shustik, E Kastritis, SP Treon, J Ping, B Hauns, I Arango-Hisijara, MA DimopoulosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.